Artificial intelligence (AI) in medicine is used to analyze complex medical data by approximating human cognition with the help of algorithms and software.
This presentation summarizes our research on 40 companies from around the world that are leveraging Artificial Intelligence to improve the Healthcare Industry. They are all well-funded, have highly qualified CEOs & Boards, and are poised to achieve their product development milestones.
The I-Square Ventures proprietary rating algorithm indicates that almost all of these companies will receive more funding, and/or be acquired by larger companies.
This document presents an overview of the AI applications in life sciences. The presentation highlights various steps in drug development and AI applications. Also, discusses Alzheimer’s disease and obstacles to develop drugs. Finally, presents details of AI in target identification for AD.
This disclaimer informs readers know that the views, thoughts, and opinions expressed in the presentation belong solely to the author, and not to the author’s employer, organization, committee or other group or individual.
Machine learning is the field that focuses on how computers learn from data. Today, machine learning is playing an integral role in the medical industry. This is due to its ability to process huge datasets beyond the scope of human capability, and then convert the data analyzed into clinical insights that aid physicians in providing care. Machine learning is a powerful, relatively easy to implement tool with numerous possibilities to enhance medical practice. The applications of machine learning in medicine are advancing medicine into a new realm. Therefore, educating the next generation of medical professionals with machine learning is essential. This paper provides a brief introduction to applying machine learning in medicine. Matthew N. O Sadiku | Sarhan M. Musa | Adedamola Omotoso "Machine Learning in Medicine: A Primer" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-2 , February 2019, URL: https://www.ijtsrd.com/papers/ijtsrd20255.pdf
Paper URL: https://www.ijtsrd.com/computer-science/other/20255/machine-learning-in-medicine-a-primer/matthew-n-o-sadiku
Everything you want to know about role of artificial intelligence in drug discovery.
Artificial intelligence in health care and pharmacy, drug discovery, tensorflow, python,
deep neural network, GANs
AI in drug discovery and development
AI in clinical trials
Artificial Intelligence and Machine Learning will have a profound effect in transforming healthcare and bridging the historical gap of information asymmetry between the healthcare ecosystem and people
This presentation summarizes our research on 40 companies from around the world that are leveraging Artificial Intelligence to improve the Healthcare Industry. They are all well-funded, have highly qualified CEOs & Boards, and are poised to achieve their product development milestones.
The I-Square Ventures proprietary rating algorithm indicates that almost all of these companies will receive more funding, and/or be acquired by larger companies.
This document presents an overview of the AI applications in life sciences. The presentation highlights various steps in drug development and AI applications. Also, discusses Alzheimer’s disease and obstacles to develop drugs. Finally, presents details of AI in target identification for AD.
This disclaimer informs readers know that the views, thoughts, and opinions expressed in the presentation belong solely to the author, and not to the author’s employer, organization, committee or other group or individual.
Machine learning is the field that focuses on how computers learn from data. Today, machine learning is playing an integral role in the medical industry. This is due to its ability to process huge datasets beyond the scope of human capability, and then convert the data analyzed into clinical insights that aid physicians in providing care. Machine learning is a powerful, relatively easy to implement tool with numerous possibilities to enhance medical practice. The applications of machine learning in medicine are advancing medicine into a new realm. Therefore, educating the next generation of medical professionals with machine learning is essential. This paper provides a brief introduction to applying machine learning in medicine. Matthew N. O Sadiku | Sarhan M. Musa | Adedamola Omotoso "Machine Learning in Medicine: A Primer" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-2 , February 2019, URL: https://www.ijtsrd.com/papers/ijtsrd20255.pdf
Paper URL: https://www.ijtsrd.com/computer-science/other/20255/machine-learning-in-medicine-a-primer/matthew-n-o-sadiku
Everything you want to know about role of artificial intelligence in drug discovery.
Artificial intelligence in health care and pharmacy, drug discovery, tensorflow, python,
deep neural network, GANs
AI in drug discovery and development
AI in clinical trials
Artificial Intelligence and Machine Learning will have a profound effect in transforming healthcare and bridging the historical gap of information asymmetry between the healthcare ecosystem and people
Big Data and its Impact on Industry (Example of the Pharmaceutical Industry)Hellmuth Broda
While we bemoan the ever increasing data tsunami new technologies allow to harvest the gold nuggets in the hay stack.
Using the example of the Pharmaceutical Industry some of the possible business uses for Big Data Analitics are outlined.
Digital platforms could disrupts how pharma companies plan and excecute clini...Jayanthi Repalli, PhD
Pharmaceutical companies spent millions of dollars every year on clinical trials. They are essential part of finding new drugs. However, the lack of participants is the major cause for the delay of trials. Digital platforms could solve this problem for pharm companies and accelerate new drug development. Hope you find this infographic useful. Feel free to drop a note!
This disclaimer informs readers know that the views, thoughts, and opinions expressed in the presentation belong solely to the author, and not to the author’s employer, organization, committee or other group or individual.
Big Data Provides Opportunities, Challenges and a Better Future in Health and...Cirdan
This presentation was delivered by Ashraf Mina, NSW Pathology at the Pathology Horizons 2017 Conference in Cairns, Australia.
Pathology Horizons 2017 is an annual CPD conference organised by Cirdan on the future of pathology. You can access more information about the event at www.pathologyhorizons.com
The company was founded in 2010 and is headquartered in Lisburn, Northern Ireland and has additional offices in Canada and Australia.
Cirdan is also responsible for organising Pathology Horizons, an annual and open CPD conference on the future of pathology. For more information visit - www.pathologyhorizons.com
From Edge Case to Main Case, Michelle Longmire of Medable_mHealth IsraelLevi Shapiro
Presentation by Michelle Longmire, CEO of Medable, April 20, 2021, for mHealth Israel. During CoVID, as physical access to clinics was limited, Medable enabled patients to continue participating in critical research efforts. Medable Supporting over 100 Studies Across a Diverse Array of Therapeutic Areas. Medable provides a platform for seamless evidence
generation, across the entire patient journey. Connecting patients globally for community, care, and research. Improve patient experience and retention. Reduce site burden. Data Cloud & Platform should be flexible and modular to enable protocol-fit digital. Medable Digitome, for data driven decentralized trials and a new era of understanding patients, therapies, and conditions. Clinical research is a small component of the broader healthcare journey. Enable health data and evidence generation from clinical to commercial, from day one. Continuous health data & evidence from clinical to commercial and beyond. The Digitome can provide a
primary observational protocol that collects large scale baseline data in a framework that enables streamlined recruitment, enrollment, and participation into interventional clinical substudies.
PLEASE NOTE: THESE SLIDES MAY NOT DISPLAY PROPERLY ONLINE, BUT THEY ARE READABLE IF DOWNLOADED.
October 28, 2018
This one-day conference explored the current pharmaceutical pricing landscape by bringing together leaders from the pharmaceutical industry, policymakers, legal practitioners, and scholars to engage in novel, interdisciplinary discussions to better understand current challenges and articulate best practices to address these issues. Participants assessed the current challenges presented in drug pricing policy, from development to delivery, in both the United States and international context. We also explored and articulated best practices to expand access to medicines and worked toward developing a plan for disseminating these practices more widely.
ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY "AN OVERVIEW OF AWARENESS"FinianCN
ARTIFICIAL INTELLIGENT IN DRUG DISCOVERY:- AN OVERVIEW OF AWARENESS.
AI is showing the potential to be a faster and more efficient way to find and develop new drugs. A growing number of organizations and universities are focusing to minimize the complexities involved in the classical way of drug discovery by using AI computing to envisage which drug candidate are most likely to be effective treatments.
It is hard to measure the adoption of AI in drug discovery. Pharma and biotech companies tend to not publicly disclose competitive technology use.
While organizations are adopting the technology, there is significant untapped potential for those willing to be more aggressive. Which is depending on the realization of the potential with education and relevant success stories
Presentation by David Farber, FDA Life Science Partner at King & Spalding, about US Reimbursement.
I. Introduction
• II. FDA Approval vs. Reimbursement
• a. Different Standards
b. Clinical Evidence Needed
• III. The Three Keys to Reimbursement
A. Coverage
B. Coding
C. Payment
• IV. What’s New for 2019
• V. Reimbursement for MedTech AI Solutions
• VI. Tips for Successful Reimbursement
How Artificial Intelligence in Transforming PharmaTyrone Systems
Artificial intelligence in Pharma refers to the use of automated algorithms to perform tasks which traditionally rely on human intelligence. Over the last five years, the use of artificial intelligence in the pharma and biotech industry has redefined how scientists develop new drugs, tackle disease, and more.
Given the growing importance of Artificial Intelligence for the pharma industry, we wanted to create a comprehensive report which helps every business leader understand the biggest breakthroughs in the biotech space which are assisted by the deployment of artificial intelligence technologies.
Hirshberg promise of digital technology astra_zenecaThe Promise of Digital Te...Levi Shapiro
Presentation by Boaz Hirshberg, VP, Clinical Development, Cardiovascular, Renal, Metabolic Disease at AstraZeneca
- The Promise of Digital Technology in Drug Development Clinical Trials. Includes the following:
- The vision for patient-centric medical care delivery
- End-to-end patient experience enhanced by digital technologies
- Digital technologies have a potential to transform clinical trial & medical care delivery
- Example: transforming our understanding of Type 2 diabetes with remote patient monitoring
- Frequent sampling demonstrates glucose lowering very soon after first dose, which might be unappreciated in typical trial design
- Multiple data points reduce uncertainty about the glucose outcome and enable future machine learning of unanticipated relationships
- Lessons learned from CGM pilot: data storage, transfer, and analysis
- Defining the clinical science questions to be answered
- Operational considerations for incorporating digital data into clinical development
- Addressing challenges of digital technologies’ disruption
Dr. Jules Mitchel, President of Target Health, delivered this presentation on the new FDA Guidance on the use of the electronic health record for clinical research at the North American eClinical Forum Autumn Meeting on October 2, 2018.
Regulatory Concerns When Running Virtual/Paperless Clinical TrialsTarget Health, Inc.
With drug and device manufacturers and the U.S. Food and Drug Administration (FDA) supplying much of the push, so-called paperless clinical trials are gaining momentum. In this eClinical Forum webinar, Dr. Jules Mitchel, President of Target Health, facilitated the discussion on the future landscape and regulatory concerns of paperless clinical trials and clinical trial design incorporating mobile tools.
Artificial Insemination Market Growth, Demand and Challenges of the Key Indus...IMARC Group
The global artificial insemination market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/artificial-insemination-market
Wearable Medical Devices Market PPT: Demand, Trends and Business Opportunitie...IMARC Group
The global wearable medical devices market size reached US$ 23.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 73 Billion by 2028, exhibiting a growth rate (CAGR) of 22% during 2023-2028.
More Info:- https://www.imarcgroup.com/wearable-medical-devices-market
Big Data and its Impact on Industry (Example of the Pharmaceutical Industry)Hellmuth Broda
While we bemoan the ever increasing data tsunami new technologies allow to harvest the gold nuggets in the hay stack.
Using the example of the Pharmaceutical Industry some of the possible business uses for Big Data Analitics are outlined.
Digital platforms could disrupts how pharma companies plan and excecute clini...Jayanthi Repalli, PhD
Pharmaceutical companies spent millions of dollars every year on clinical trials. They are essential part of finding new drugs. However, the lack of participants is the major cause for the delay of trials. Digital platforms could solve this problem for pharm companies and accelerate new drug development. Hope you find this infographic useful. Feel free to drop a note!
This disclaimer informs readers know that the views, thoughts, and opinions expressed in the presentation belong solely to the author, and not to the author’s employer, organization, committee or other group or individual.
Big Data Provides Opportunities, Challenges and a Better Future in Health and...Cirdan
This presentation was delivered by Ashraf Mina, NSW Pathology at the Pathology Horizons 2017 Conference in Cairns, Australia.
Pathology Horizons 2017 is an annual CPD conference organised by Cirdan on the future of pathology. You can access more information about the event at www.pathologyhorizons.com
The company was founded in 2010 and is headquartered in Lisburn, Northern Ireland and has additional offices in Canada and Australia.
Cirdan is also responsible for organising Pathology Horizons, an annual and open CPD conference on the future of pathology. For more information visit - www.pathologyhorizons.com
From Edge Case to Main Case, Michelle Longmire of Medable_mHealth IsraelLevi Shapiro
Presentation by Michelle Longmire, CEO of Medable, April 20, 2021, for mHealth Israel. During CoVID, as physical access to clinics was limited, Medable enabled patients to continue participating in critical research efforts. Medable Supporting over 100 Studies Across a Diverse Array of Therapeutic Areas. Medable provides a platform for seamless evidence
generation, across the entire patient journey. Connecting patients globally for community, care, and research. Improve patient experience and retention. Reduce site burden. Data Cloud & Platform should be flexible and modular to enable protocol-fit digital. Medable Digitome, for data driven decentralized trials and a new era of understanding patients, therapies, and conditions. Clinical research is a small component of the broader healthcare journey. Enable health data and evidence generation from clinical to commercial, from day one. Continuous health data & evidence from clinical to commercial and beyond. The Digitome can provide a
primary observational protocol that collects large scale baseline data in a framework that enables streamlined recruitment, enrollment, and participation into interventional clinical substudies.
PLEASE NOTE: THESE SLIDES MAY NOT DISPLAY PROPERLY ONLINE, BUT THEY ARE READABLE IF DOWNLOADED.
October 28, 2018
This one-day conference explored the current pharmaceutical pricing landscape by bringing together leaders from the pharmaceutical industry, policymakers, legal practitioners, and scholars to engage in novel, interdisciplinary discussions to better understand current challenges and articulate best practices to address these issues. Participants assessed the current challenges presented in drug pricing policy, from development to delivery, in both the United States and international context. We also explored and articulated best practices to expand access to medicines and worked toward developing a plan for disseminating these practices more widely.
ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY "AN OVERVIEW OF AWARENESS"FinianCN
ARTIFICIAL INTELLIGENT IN DRUG DISCOVERY:- AN OVERVIEW OF AWARENESS.
AI is showing the potential to be a faster and more efficient way to find and develop new drugs. A growing number of organizations and universities are focusing to minimize the complexities involved in the classical way of drug discovery by using AI computing to envisage which drug candidate are most likely to be effective treatments.
It is hard to measure the adoption of AI in drug discovery. Pharma and biotech companies tend to not publicly disclose competitive technology use.
While organizations are adopting the technology, there is significant untapped potential for those willing to be more aggressive. Which is depending on the realization of the potential with education and relevant success stories
Presentation by David Farber, FDA Life Science Partner at King & Spalding, about US Reimbursement.
I. Introduction
• II. FDA Approval vs. Reimbursement
• a. Different Standards
b. Clinical Evidence Needed
• III. The Three Keys to Reimbursement
A. Coverage
B. Coding
C. Payment
• IV. What’s New for 2019
• V. Reimbursement for MedTech AI Solutions
• VI. Tips for Successful Reimbursement
How Artificial Intelligence in Transforming PharmaTyrone Systems
Artificial intelligence in Pharma refers to the use of automated algorithms to perform tasks which traditionally rely on human intelligence. Over the last five years, the use of artificial intelligence in the pharma and biotech industry has redefined how scientists develop new drugs, tackle disease, and more.
Given the growing importance of Artificial Intelligence for the pharma industry, we wanted to create a comprehensive report which helps every business leader understand the biggest breakthroughs in the biotech space which are assisted by the deployment of artificial intelligence technologies.
Hirshberg promise of digital technology astra_zenecaThe Promise of Digital Te...Levi Shapiro
Presentation by Boaz Hirshberg, VP, Clinical Development, Cardiovascular, Renal, Metabolic Disease at AstraZeneca
- The Promise of Digital Technology in Drug Development Clinical Trials. Includes the following:
- The vision for patient-centric medical care delivery
- End-to-end patient experience enhanced by digital technologies
- Digital technologies have a potential to transform clinical trial & medical care delivery
- Example: transforming our understanding of Type 2 diabetes with remote patient monitoring
- Frequent sampling demonstrates glucose lowering very soon after first dose, which might be unappreciated in typical trial design
- Multiple data points reduce uncertainty about the glucose outcome and enable future machine learning of unanticipated relationships
- Lessons learned from CGM pilot: data storage, transfer, and analysis
- Defining the clinical science questions to be answered
- Operational considerations for incorporating digital data into clinical development
- Addressing challenges of digital technologies’ disruption
Dr. Jules Mitchel, President of Target Health, delivered this presentation on the new FDA Guidance on the use of the electronic health record for clinical research at the North American eClinical Forum Autumn Meeting on October 2, 2018.
Regulatory Concerns When Running Virtual/Paperless Clinical TrialsTarget Health, Inc.
With drug and device manufacturers and the U.S. Food and Drug Administration (FDA) supplying much of the push, so-called paperless clinical trials are gaining momentum. In this eClinical Forum webinar, Dr. Jules Mitchel, President of Target Health, facilitated the discussion on the future landscape and regulatory concerns of paperless clinical trials and clinical trial design incorporating mobile tools.
Artificial Insemination Market Growth, Demand and Challenges of the Key Indus...IMARC Group
The global artificial insemination market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/artificial-insemination-market
Wearable Medical Devices Market PPT: Demand, Trends and Business Opportunitie...IMARC Group
The global wearable medical devices market size reached US$ 23.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 73 Billion by 2028, exhibiting a growth rate (CAGR) of 22% during 2023-2028.
More Info:- https://www.imarcgroup.com/wearable-medical-devices-market
DNA Sequencing Products Market by Product Type, Distribution Channel, End Use...IMARC Group
The global DNA sequencing products market size reached US$ 6.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 11.4 Billion by 2028, exhibiting a growth rate (CAGR) of 9.76% during 2023-2028.
More Info:- https://www.imarcgroup.com/dna-sequencing-products-market
Global artificial intelligenceGlobal Artificial Intelligence (AI) for Drug Di...GMI Research
Global AI for Drug Discovery Market by Drug Type (Small Molecule and Large Molecules), By Technology (Deep Learning and machine learning), By Therapeutic Type (Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases and Others) End-Users (Pharmaceutical Companies, Biopharmaceutical Companies, Academic and Research Institutes and Others) and by Geography – Opportunities & Forecast, 2018-2025
The global brain monitoring market generated revenue of US$ 5.5 billion in 2020 and is expected to reach US$ 7.5 billion by 2025 with a CAGR of 6.5% in the forecast period. Growing incidences of neurological disorders & brain injury, growing geriatric population, and increasing investment in the medical sector to provide advanced research & treatment are the key factors driving the growth of the global brain monitoring market.
Companion Diagnostics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...IMARC Group
The global companion diagnostics market size reached US$ 5.0 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 11.7 Billion by 2027, exhibiting a growth rate (CAGR) of 14.78% during 2022-2027.
More Info:- https://www.imarcgroup.com/companion-diagnostics-market
Regenerative Medicine Market PPT 2021: Size, Growth, Demand and Forecast till...IMARC Group
As per the latest report by IMARC Group,the global Regenerative medicine market size reached a strong growth in 2020.
Regenerative medicines refer to an interdisciplinary field that plays a vital role in tissue and organ transplants.
Veterinary Diagnostics Market PPT 2024: Size, Growth, Demand and Forecast til...IMARC Group
The global veterinary diagnostics market size reached US$ 6.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.3% during 2024-2032.
More Info:- https://www.imarcgroup.com/veterinary-diagnostics-market
Home Medical Equipment Market PPT: Growth, Outlook, Demand, Keyplayer Analysi...IMARC Group
The global home medical equipment market size reached US$ 37.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 53.7 Billion by 2028, exhibiting a growth rate (CAGR) of 6.4% during 2023-2028.
More Info:- https://www.imarcgroup.com/home-medical-equipment-market
High Content Screening Market PPT: Demand, Trends and Business Opportunities ...IMARC Group
The global high content screening market size reached US$ 1.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.0 Billion by 2028, exhibiting a growth rate (CAGR) of 8.4% during 2023-2028.
More Info:- https://www.imarcgroup.com/high-content-screening-market
The global in-vitro diagnostics market size was valued at US$ 60,274.1 million in 2017, and is expected to exhibit a CAGR of 4.6% over the forecast period (2018–2026).
The global whole slide imaging market size reached US$ 690.3 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,340.8 Million by 2028, exhibiting a growth rate (CAGR) of 11.5% during 2023-2028.
More Info:- https://www.imarcgroup.com/whole-slide-imaging-market
The global brain monitoring market generated revenue of US$ 5.5 billion in 2020 and is expected to reach US$ 7.5 billion by 2025 with a CAGR of 6.5% in the forecast period. Growing incidences of neurological disorders & brain injury, growing geriatric population, and increasing investment in the medical sector to provide advanced research & treatment are the key factors driving the growth of the global brain monitoring market.
Laboratory Information System Market Research Reportreport sellers
Global Laboratory Information System market is expected to grow from $1.37 billion in 2016 to reach $2.65 billion by 2023 with a CAGR of 9.8%.For more information please visit https://www.reportsellers.com/market-research-report/Laboratory-Information-System---Global-Market
PPT-Computational Biology Market Growth, Demand and Challenges of the Key In...IMARC Group
According to the latest report by IMARC Group, the global computational biology market reached a value of US$ 3.9 Billion in 2021. Computational biology refers to a branch of biology that involves the application of computer science to study the processes of life. It involves the utilization of various computational methods for the simulation and representation of biological systems on a large scale. Some of the popular adopted methods include algorithms, machine learning (ML), statistical physics, robotics and complexity theory that aid in determining the cellular function and treatment for multiple diseases.
PPT-Metagenomics Market Growth, Demand and Challenges of the Key Industry Pl...IMARC Group
According to the latest report by IMARC Group,the global metagenomics market exhibited strong growth during 2015-2020.Metagenomics refers to the research field that assists researchers in studying the characteristics of genetic substances that are acquired from environmental samples. It involves the usage of multiple molecular tools, such as bioinformatics and sequencing techniques, in order to determine the insights of microbial genomes and analyze the structure of the human microbiome.
Cell Therapy Market PPT: Demand, Trends and Business Opportunities 2023-28IMARC Group
The global cell therapy market size reached US$ 11.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 32.1 Billion by 2028, exhibiting a growth rate (CAGR) of 17.5% during 2023-2028.
More Info:- https://www.imarcgroup.com/cell-therapy-market
Artificial intelligence in healthcare market global trends, market share, ind...Shubham Bhosale
Global Artificial Intelligence in Healthcare Market is estimated to value over USD 37 billion by 2029 end and is expected to register a CAGR of over 50% during the forecast period 2019 to 2029.
The artificial intelligence (AI) is capable of improving patient outcomes by accurately identifying the source cause of the disease, this is positively influencing the market growth.
Global Refurbished Medical Devices Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast 2018-2023
Refurbished Medical Devices Market, Increasing adoption of low cost refurbished equipment, rising demand in emerging economies due to budget constraints, increasing privatization of healthcare sector, rise in sales due to online marketing are the key factors that driving the market. The global refurbished devices market is segmented into type of devices, application and end user.
Digital pathology market is expected to grow from US$ 952.62 million in 2022 to US$ 1,892.40 million by 2028; it is estimated to grow at a CAGR of 12.1% from 2022 to 2028.
Similar to Artificial Intelligence in Medicine Market Report Size 2021 ppt (20)
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
2. Artificial Intelligence in Medicine Market - Global Opportunity Analysis & Industry Forecast
2021 - 2025
Artificial Intelligence in Medicine Market by Product Type (Hardware, Software, and Services),
Technology (Deep Learning, Querying Method, Natural Language Processing, and Context Aware
Processing), and Application (Drug Discovery & Repurposing, Clinical Research Trial, Personalized
Medicine, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025
3. Artificial Intelligence in Medicine Market - Overview:
Different interventions that range from identification of patients and maintenance of their records during
clinical trials, to application in drug discovery and repurposing are gradually incorporating artificial
intelligence, thereby revolutionizing drug discovery and development setting.
In the field of medicine, artificial intelligence (AI) can be used for research studies and applications that
support decision-based medical tasks using data-intensive computer-based solutions. For every drug that
is launched in the market, the pharmaceutical industry spends on an average $2.7 billion, which
amortizes the losses incurred from the aborted pipelines. Almost 90% of all drug programs that reach
clinical trial stages are aborted. Thus, many large pharma and academic research institutions are focusing
on use of AI to increase efficiencies and design better drugs.
4. Artificial Intelligence in Medicine Market - Major Key Players
• Welltok, Inc., Intel Corporation, Nvidia Corporation, Google Inc., IBM Corporation, Microsoft
Corporation, General Vision, Inc., Enlitic, Inc., BioXcel Corporation, and Berg Health.
• Other prominent players in the value chain include InSilico Medicine, Inc., Globavir Biosciences, Inc.,
GNS Healthcare, Flatiron Health, Benevolent AI, Atomwise, Verge Genomics, Cloud Pharmaceuticals,
and Recursion Pharmaceuticals.
Read More@ https://www.alliedmarketresearch.com/artificial-intelligence-in-
medicine-market
5. Artificial Intelligence in Medicine Market Market & COVID-19
COVID-19 Scenario:
• Due to the global pandemic all over the world, the medical devices manufacturers are majorly focusing
on essential medical devices production including ventilators and diagnostics.
• However, due to the precautionary measures taken by governments in various regions, the supply
chain has been hampered. Which may result in shortage of devices in certain locations.
• Food and Drugs Administration (FDA), on the other hand, shared a COVID-19 guidance with medical
device manufacturers to notify the agency about changes that could affect availability of their
products.
Get detailed COVID-19 impact analysis on the Market@
https://www.alliedmarketresearch.com/request-for-customization/4749?reqfor=covid
6. Artificial Intelligence in Medicine Market – Regional outlook
The market is evaluated based on its regional penetration, explaining the performance of the market
in each regional market covering regions such as North America (United States, Canada and Mexico),
Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast
Asia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt,
Nigeria and South Africa)
Get Free Sample PDF of Report@ https://www.alliedmarketresearch.com/request-sample/4749
7. About Us:-
Allied Market Research (AMR) is a market research and business-consulting firm of
Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports,
business solutions, consulting services, and insights on markets across 11 industry
verticals. Adopting extensive research methodologies, AMR is instrumental in helping
its clients to make strategic business decisions and achieve sustainable growth in
their market domains. We are equipped with skilled analysts and experts, and have a
wide experience of working with many Fortune 500 companies and small & medium
enterprises.
Visit Or Website@ https://www.alliedmarketresearch.com
8. Contact Us:
• David Correa
• 5933 NE Win Sivers Drive
• #205, Portland, OR 97220
• United States
• USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
• UK: +44-845-528-1300
• Hong Kong: +852-301-84916
• India (Pune): +91-20-66346060